Bulletin du cancer最新文献

[Prevalence of breast arterial calcification in women who underwent a breast cancer screening in the Hauts-de-France]. [在上法兰西省接受乳腺癌筛查的妇女中乳腺动脉钙化的患病率]。

IF 0.8

Bulletin du cancer Pub Date : 2025-07-30 DOI: 10.1016/j.bulcan.2025.07.002

Anissa Assaf, Marie-Laure Forzy, Valérie Pétigny, Edouard Poncelet, Luc Ceugnart

引用次数: 0

[Treatment guidelines for patients with relapsed/progressive high-risk neuroblastoma from the Neuroblastoma Committee of the French Society of Pediatric Oncology]. [法国儿科肿瘤学会神经母细胞瘤委员会对复发/进展性高危神经母细胞瘤患者的治疗指南]。

Bulletin du cancer Pub Date : 2025-07-24 DOI: 10.1016/j.bulcan.2025.04.006

Pablo Berlanga, Claudia Pasqualini, Marion Gambart, Benoit Dumont, Estelle Thebaud, Julie Tandonnet, Joy Benadiba, Amaury Leruste, Carole Coze, Gudrun Schleiermacher, Anne Sophie Defachelles

{"title":"[Treatment guidelines for patients with relapsed/progressive high-risk neuroblastoma from the Neuroblastoma Committee of the French Society of Pediatric Oncology].","authors":"Pablo Berlanga, Claudia Pasqualini, Marion Gambart, Benoit Dumont, Estelle Thebaud, Julie Tandonnet, Joy Benadiba, Amaury Leruste, Carole Coze, Gudrun Schleiermacher, Anne Sophie Defachelles","doi":"10.1016/j.bulcan.2025.04.006","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.04.006","url":null,"abstract":"The prognosis for patients with high-risk neuroblastoma in the event of disease relapse/progression after first line therapy remains poor. However, over the past decade, new therapies have emerged that offer physicians, families and patients the hope of tumor control and, in some cases, a cure. Given the rapid evolution of new therapies in this field, it is strongly recommended that such cases be discussed at a multidisciplinary level and with patients/families regarding treatment options based on existing data. We summarize here the recommendations of the Neuroblastoma Committee of the Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'adolescent (SFCE) for the treatment of patients with high-risk neuroblastoma in relapse/progression in France. These recommendations concern chemoimmunotherapy, the combination of ALK inhibitors with chemotherapy, and consolidation treatment options in the absence of tumor progression, as well as the place for early clinical trials.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Management for HSC collected from related donor living in Maghreb for a patient transplanted in a France (SFGM-TC)]. [在法国移植的患者从马格里布的亲属供体收集的HSC的管理（SFGM-TC）]。

Bulletin du cancer Pub Date : 2025-07-23 DOI: 10.1016/j.bulcan.2025.04.009

Christine Giraud, Virginie Ader, Kahina Amokrane, Malek Benakli, Silva-Maria Bezsera, Isabelle Hascoet Leberre, Laetitia Le Bars, Jessica Letoffet, Thomas Piot, Marie Poullain, Marie Talouarn, Anne Wallart, Leonardo Magro, Nabil Yafour

{"title":"[Management for HSC collected from related donor living in Maghreb for a patient transplanted in a France (SFGM-TC)].","authors":"Christine Giraud, Virginie Ader, Kahina Amokrane, Malek Benakli, Silva-Maria Bezsera, Isabelle Hascoet Leberre, Laetitia Le Bars, Jessica Letoffet, Thomas Piot, Marie Poullain, Marie Talouarn, Anne Wallart, Leonardo Magro, Nabil Yafour","doi":"10.1016/j.bulcan.2025.04.009","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.04.009","url":null,"abstract":"Human stem cell (bone marrow, peripheral blood stem cell and mononuclear cell) transplantation from donors living outside France for allogeneic graft to patients transplanted in a francophone centers is likely to develop with Maghreb countries associated with the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Considering requirements from JACIE (version 8, soon version 9) and the good practices for cellular therapy, the SFGM-TC decided to create a working group to align France and Maghreb on common documents and procedures to facilitate human stem cell collection considering the following criteria: journey and care of foreign donor, information document, medical prescription, labelling, transport and import authorization of blood samples and grafts. This work requires collaboration with the French Biomedical Agency that provides connection between the medical center of recipient patient and the medical center of foreign donor registered on the World Marrow Donor Association.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144710289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[About therapeutic innovation in oncology]. [关于肿瘤学治疗创新]。

Bulletin du cancer Pub Date : 2025-07-23 DOI: 10.1016/j.bulcan.2025.04.012

Dominique Levêque

引用次数: 0

[Radiation-induced ototoxicity during the treatment of head, neck and skull base cancers]. [头颈颅底肿瘤治疗期间的辐射致耳毒性]。

Bulletin du cancer Pub Date : 2025-07-23 DOI: 10.1016/j.bulcan.2025.06.007

Rafik Nebbache, Florence Huguet, Juliette Thariat, Charles Maquet, Fabrice Giraudet, François-Régis Ferrand

引用次数: 0

[Factors influencing active lifestyle beyond cancer in metropolitan France: The DEFACTO qualitative study]. [影响法国大城市癌症以外积极生活方式的因素：DEFACTO定性研究]。

Bulletin du cancer Pub Date : 2025-07-23 DOI: 10.1016/j.bulcan.2025.04.010

Albane Aumaitre, Rémi Gagnayre, Aude-Marie Foucaut

{"title":"[Factors influencing active lifestyle beyond cancer in metropolitan France: The DEFACTO qualitative study].","authors":"Albane Aumaitre, Rémi Gagnayre, Aude-Marie Foucaut","doi":"10.1016/j.bulcan.2025.04.010","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.04.010","url":null,"abstract":"Introduction: Adopting and maintaining an active lifestyle, including regular physical activity and limiting prolonged sedentary behaviour, are recommended beyond cancer. However, achieving these recommendations is not always straightforward for patients. The aim of this study is to identify factors that contribute to an active lifestyle post-cancer, based on individuals' experiences.Methods: Semi-structured interviews were conducted with 18 individuals who had completed treatments for breast, lung, colorectal, or prostate cancer. A content analysis was performed using NVivo® software.Results: The socio-ecological model highlights the influence of micro-, meso-, and macro-level environments. The micro-level includes individual perceptions of an active lifestyle, coping strategies, and priority management. The meso-level highlights social and family support, preparation for post-cancer phase by healthcare professionals, and accessibility of resources. The macro-level addresses perceived inconsistencies in public health messaging from the media, urban air quality, policies for securing active mobility spaces, reimbursement of services, and the relationship between urban settings and hospitals.Discussion: The factors influencing an active lifestyle are interdependent and complex, and their diversity necessitates a multimodal and comprehensive support approach, including educational interventions on modifiable factors.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144710288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Targeted therapies in neoadjuvant breast cancer: The role of CDK4/6 and PARP inhibitors]. 靶向治疗新辅助乳腺癌：CDK4/6和PARP抑制剂的作用。

Bulletin du cancer Pub Date : 2025-07-16 DOI: 10.1016/j.bulcan.2025.06.005

Thomas Papazyan, Jean-Sébastien Frénel

{"title":"[Targeted therapies in neoadjuvant breast cancer: The role of CDK4/6 and PARP inhibitors].","authors":"Thomas Papazyan, Jean-Sébastien Frénel","doi":"10.1016/j.bulcan.2025.06.005","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.06.005","url":null,"abstract":"Over the past decade, targeted therapies have significantly improved the prognosis of metastatic breast cancer. CDK4/6 and PARP inhibitors are now gaining traction in the adjuvant setting, and their potential use in the neoadjuvant context is also being explored. This review presents an analysis of the current scientific evidence and associated clinical perspectives. CDK4/6 inhibitors act on cell cycle dysregulation, commonly observed in hormone receptor-positive breast cancers. In the adjuvant setting, abemaciclib and ribociclib have shown improvements in progression-free survival (PFS) in the monarchE and NATALEE trials, respectively, leading to their approval by the European Medicines Agency. In the neoadjuvant context, although these agents have demonstrated a reduction in proliferation markers such as Ki67, their impact on clinical practice remains limited to date. PARP inhibitors are based on the concept of synthetic lethality, specifically targeting cancers with germline BRCA1 or BRCA2 mutations. In the adjuvant setting, the OlympiA trial demonstrated a significant improvement in both PFS and overall survival (OS). In the neoadjuvant setting, these agents have also shown effects on pathological markers, though the clinical relevance of these findings has yet to be clearly established. Overall, these results underscore the growing role of targeted therapies in the adjuvant management of breast cancer. The identification and validation of predictive biomarkers will be crucial in optimizing their use, both in adjuvant and neoadjuvant settings.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[End of COBE2991®: What alternatives are available for the preparation of each type of cell therapy products? (SFGM-TC)]. [COBE2991®结束：每种类型的细胞治疗产品的制备有哪些替代品？](SFGM-TC)]。

Bulletin du cancer Pub Date : 2025-07-16 DOI: 10.1016/j.bulcan.2025.04.008

Justine Nasone, Carina Alves Goncalves, Caroline Ballot, Ulrick Birba, Maxime Bouabdelli, Lucille Capin, Alexandra Clerc, Marie Agnès Guerout Vérité, Khadija Hajjout, Antoine Haquette, Xavier Lafarge, Elisa Magrin, Florence Pierre, Eden Schwartz, Boris Calmels, Hélène Rouard, Leonardo Magro, Valérie Mialou

引用次数: 0

Epidemiological trends of hematological malignancies in North Africa: Recent insights. 北非血液恶性肿瘤的流行病学趋势：最近的见解。

Bulletin du cancer Pub Date : 2025-07-15 DOI: 10.1016/j.bulcan.2025.04.013

Salma Madihi, Hind Bouafi, Samia Boukaira, Siham Bennani, Abdelouaheb Benani

{"title":"Epidemiological trends of hematological malignancies in North Africa: Recent insights.","authors":"Salma Madihi, Hind Bouafi, Samia Boukaira, Siham Bennani, Abdelouaheb Benani","doi":"10.1016/j.bulcan.2025.04.013","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.04.013","url":null,"abstract":"Introduction: Hematologic malignancies (HMs) remain the leading cause of the global tumor burden, with growing absolute numbers. Real-world data in North Africa regarding HMs are lacking. Therefore, we aimed to report the updated insights into the prevalence, incidence, and mortality rates of HMs in North African countries to guide patient care and health policy in the region.Methods: Epidemiological data on the incidence, prevalence and mortality of HMs, including sex, age, and age-standardized rate (ASR) of HM in North African countries from 1992 to 2024 were extracted from different electronic databases.Results: Our results indicate that non-Hodgkin lymphoma (NHL) is the most prevalent HM in North Africa, exhibiting the highest incidence and mortality rates, followed by leukemia, Hodgkin lymphoma (HL) and multiple myeloma (MM), with a male predominance. Specifically, most NHL subtypes in North African countries are nodal and aggressive, including DLBCL, MALT, mantle cell lymphoma, and anaplastic B-cell lymphoma. In adolescents and children, leukemia is the first group of neoplasms reported in the region. The most frequent types are (acute leukemia) AL, including acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML), also with a male predominance. Other risk factors are linked to HMs, including bacterial and viral ones, diabetes mellitus, autoimmunity and genetic disorders.Conclusion: These findings underline the importance of region- and gender-specific research to guide healthcare policies and improve patient care.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[De-escalation in axillary breast cancer surgery: Real-life applications]. [腋窝乳腺癌手术的降级：现实应用]。

Bulletin du cancer Pub Date : 2025-07-15 DOI: 10.1016/j.bulcan.2025.06.006

Claire Bonin-Mouriot, Marie Gosset, Yann Delpech, Caroline Bailleux, Emmanuel Barranger

{"title":"[De-escalation in axillary breast cancer surgery: Real-life applications].","authors":"Claire Bonin-Mouriot, Marie Gosset, Yann Delpech, Caroline Bailleux, Emmanuel Barranger","doi":"10.1016/j.bulcan.2025.06.006","DOIUrl":"https://doi.org/10.1016/j.bulcan.2025.06.006","url":null,"abstract":"The indications for axillary lymph node dissection (ALND) have been reduced in breast cancer surgery. At the same time, maintenance treatments have become more complex. This paradox makes it essential to assess whether de-escalation might underestimate lymph node invasion, resulting in a loss of chance for patients eligible for these treatments. The aim is to determine the factors for lymph node invasion ≥4N+ in primary surgery, and for complete histological lymph node non-response in neoadjuvant chemotherapy, and then to assess the proportion of patients with an indication for ALND, and the proportion of patients eligible for enhanced maintenance treatment, in 2023. This is a single-centre retrospective study conducted at the Centre Antoine Lacassagne, involving patients treated for breast cancer with subclinical lymph node involvement between 2014 and 2020. In primary surgery, 62.9% had lymph node involvement <4N+. The predictive factor for lymph node involvement ≥4N+ was loss of ovality on ultrasound (P=0.01). After neoadjuvant chemotherapy, 45.7% had a complete histological lymph node response. MRI of the breast and axilla was the best predictor of this response (P=0.007). Twenty-nine percent of primary surgery patients were eligible for sentinel node therapy, with only one eligible for maintenance treatment. After neoadjuvant chemotherapy, 46% could have avoided ALND without compromising maintenance treatments. Under the new recommendations, 35% of patients could have avoided ALND. Ultrasound is the best preoperative examination for primary surgery. MRI is preferable for predicting response to neoadjuvant chemotherapy. There is no loss of chance for patients eligible for the new adjuvant treatments.","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0